HRT Financial LP, identified as a 10% shareholder in Bluejay Diagnostics, Inc. (NASDAQ:BJDX), has disclosed a mixed portfolio of transaction activity involving the company's common equity. The investment firm executed both sales and purchases, selling shares totaling $48,913 in value while acquiring additional stock valued at $96,710. This dual activity occurs as the equity has demonstrated notable short-term momentum, rising 25% over the trailing week, despite maintaining a significant 77% decline over the past year. Independent analysis indicates the stock may currently trade above its established fair value, suggesting potential overvaluation at present price points.
On July 10, 2026, HRT Financial LP disposed of 34,938 shares of Bluejay Diagnostics common stock. The disposal was executed at a price of $1.40 per share. Following this divestment, the firm's direct holding decreased to 92,055 shares. Prior to this sale, on July 9, 2026, HRT Financial LP acquired 64,047 shares of the same common stock. The acquisition was completed at a price of $1.51 per share, resulting in a direct ownership position of 126,993 shares immediately following the purchase. These sequential transactions highlight a period of active position management by the institutional holder.
Concurrently, Bluejay Diagnostics has finalized a private placement offering that generated $8.5 million in gross proceeds. The company issued 3,655,917 shares of common stock alongside pre-funded warrants, priced at $2.325 per share. In conjunction with the equity issuance, Bluejay Diagnostics issued series G and series H warrants. These financial instruments grant the holder the right to purchase an additional 3,655,917 shares each at an exercise price of $2.075 per share. The company confirmed that these warrants are immediately exercisable, providing immediate liquidity options for investors.
Operational developments also include a strategic partnership with Argonaut Manufacturing Services. This collaboration aims to establish manufacturing capabilities within the United States for the company's Symphony platform, which is currently in clinical development. The agreement is designed to support domestic product distribution and reduce reliance on overseas manufacturing operations. These combined financial and operational moves underscore Bluejay Diagnostics' efforts to strengthen its balance sheet and enhance its operational footprint.